With a cash runway that could run out of tarmac in the next six months, British biotech Freeline Therapeutics is considering the offer of a buyout from its majority shareholder Syncona. The London-based investment firm made a nonbinding proposal yesterday to acquire the biotech for $5 per American depository share, Freeline confirmed in a Securities and Exchange Commission filing. Source: Fierce Biotech 19/10/2023